Equity.Guru Podcast: Titan Pharmaceuticals (TTNP.NASDAQ)

02/15/2019

Titan Pharmaceuticals (TTNP.Q) is an American pharmaceutical company based out of San Francisco, California. The company has recently relaunched Probuphine, its six-month treatment for Opioid Use Disorder (OUD).

The company reacquired the rights to Probuphine from Braeburn Pharmaceuticals. Since the June 2018 relaunch, sales of Probuphine have increased over 20% and the company has doubled its staff.

The Center for Disease Control says 130 Americans die every day from an opioid overdose. We spoke to Kate DeVarney, Titan’s CSO and executive vice president , about the life-changing effect Probuphine can have on someone struggling with opioid addiction and the company’s pilot program for treating OUD within Nevada’s prison population.

Listen in!

Subscribe to our iTunes channel to get your episodes hot off the press!

Related Posts

Latest Post

Leave a Reply

Your email address will not be published. Required fields are marked *